Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867017221708972032 |
|---|---|
| author | Hyunjae Shin Seung Up Kim Byeong Geun Song Youngsu Park Yunmi Ko Jeayeon Park Moon Haeng Hur Yun Bin Lee Eun Ju Cho Jeong‐Hoon Lee Su Jong Yu Jung‐Hwan Yoon Dong Hyun Sinn Yoon Jun Kim |
| author_facet | Hyunjae Shin Seung Up Kim Byeong Geun Song Youngsu Park Yunmi Ko Jeayeon Park Moon Haeng Hur Yun Bin Lee Eun Ju Cho Jeong‐Hoon Lee Su Jong Yu Jung‐Hwan Yoon Dong Hyun Sinn Yoon Jun Kim Hyunjae Shin Seung Up Kim Byeong Geun Song Youngsu Park Yunmi Ko Jeayeon Park Moon Haeng Hur Yun Bin Lee Eun Ju Cho Jeong‐Hoon Lee Su Jong Yu Jung‐Hwan Yoon Dong Hyun Sinn Yoon Jun Kim |
| collection | Wiley Open Access |
| contents | Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study Hyunjae Shin Seung Up Kim Byeong Geun Song Youngsu Park Yunmi Ko Jeayeon Park Moon Haeng Hur Yun Bin Lee Eun Ju Cho Jeong‐Hoon Lee Su Jong Yu Jung‐Hwan Yoon Dong Hyun Sinn Yoon Jun Kim Hepatology Research AbstractAimAntiviral treatment reduces the risk of developing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. However, there is a lack of high‐quality evidence regarding the preventive effects of tenofovir alafenamide (TAF) on HCC. We evaluated the impact of TAF use after curative treatment on HCC recurrence.MethodsPatients who underwent surgery or radiofrequency ablation as a curative treatment for HCC were selected. Those patients who continued antiviral treatment with nucleos(t)ide analogs (NAs; entecavir [ETV] or tenofovir disoproxil fumarate [TDF]) or switched to TAF were included. The primary outcome was HCC recurrence, and the time‐varying effect of NA use on HCC recurrence was analyzed using various statistical methods.ResultsAmong 2794 consecutive patients with chronic hepatitis B who received curative treatment for HCC, 199 subsequently switched from ETV or TDF to TAF. After a median of 3.0 years, 1303 patients (46.6%) experienced HCC recurrence. After propensity score matching (ratio 1:10), switching to TAF was not associated with an increased HCC recurrence (HR 1.00, 95% CI 0.68–1.47; p = 1.00) by time‐varying Cox analysis. Switching to TAF was not associated with HCC recurrence in subgroups of NA (HR 1.06, 95% CI 0.67–1.67; p = 0.81 for TDF, and HR 1.09, 95% CI 0.51–2.33; p = 0.82 for ETV). Kaplan–Meier analysis showed comparable HCC recurrence‐free survival between patients who switched to TAF and those who continued with their NA (p = 0.08). Time‐varying Cox analyses in various subgroups confirmed the primary findings.ConclusionsTAF is as effective as TDF and ETV in preventing HCC recurrence after curative treatment. 10.1111/hepr.14021 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/hepr.14021 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_hepr_14021 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study Hyunjae Shin Seung Up Kim Byeong Geun Song Youngsu Park Yunmi Ko Jeayeon Park Moon Haeng Hur Yun Bin Lee Eun Ju Cho Jeong‐Hoon Lee Su Jong Yu Jung‐Hwan Yoon Dong Hyun Sinn Yoon Jun Kim Hepatology Research Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study Hyunjae Shin Seung Up Kim Byeong Geun Song Youngsu Park Yunmi Ko Jeayeon Park Moon Haeng Hur Yun Bin Lee Eun Ju Cho Jeong‐Hoon Lee Su Jong Yu Jung‐Hwan Yoon Dong Hyun Sinn Yoon Jun Kim Hepatology Research AbstractAimAntiviral treatment reduces the risk of developing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. However, there is a lack of high‐quality evidence regarding the preventive effects of tenofovir alafenamide (TAF) on HCC. We evaluated the impact of TAF use after curative treatment on HCC recurrence.MethodsPatients who underwent surgery or radiofrequency ablation as a curative treatment for HCC were selected. Those patients who continued antiviral treatment with nucleos(t)ide analogs (NAs; entecavir [ETV] or tenofovir disoproxil fumarate [TDF]) or switched to TAF were included. The primary outcome was HCC recurrence, and the time‐varying effect of NA use on HCC recurrence was analyzed using various statistical methods.ResultsAmong 2794 consecutive patients with chronic hepatitis B who received curative treatment for HCC, 199 subsequently switched from ETV or TDF to TAF. After a median of 3.0 years, 1303 patients (46.6%) experienced HCC recurrence. After propensity score matching (ratio 1:10), switching to TAF was not associated with an increased HCC recurrence (HR 1.00, 95% CI 0.68–1.47; p = 1.00) by time‐varying Cox analysis. Switching to TAF was not associated with HCC recurrence in subgroups of NA (HR 1.06, 95% CI 0.67–1.67; p = 0.81 for TDF, and HR 1.09, 95% CI 0.51–2.33; p = 0.82 for ETV). Kaplan–Meier analysis showed comparable HCC recurrence‐free survival between patients who switched to TAF and those who continued with their NA (p = 0.08). Time‐varying Cox analyses in various subgroups confirmed the primary findings.ConclusionsTAF is as effective as TDF and ETV in preventing HCC recurrence after curative treatment. 10.1111/hepr.14021 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study |
| topic | Hepatology Research |
| url | https://onlinelibrary.wiley.com/doi/10.1111/hepr.14021 |